LivaNova PLC Reports Strong Q4 2025 Earnings with Double-Digit Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy LIVN?
Source: Yahoo Finance
- Significant Revenue Growth: LivaNova PLC reported Q4 2025 revenue of $361 million, a 9.5% increase, with cardiopulmonary revenue reaching $207 million, up 10% year-over-year, demonstrating strong performance in the medical device market and reinforcing its market position.
- Improved Profitability: The adjusted operating income stood at $64 million, maintaining an 18% margin consistent with the previous year, reflecting effective cost control and operational efficiency, which enhances confidence in future investments.
- Robust Cash Flow: By the end of 2025, LivaNova's cash balance reached $636 million, up from $429 million at the end of 2024, while adjusted free cash flow totaled $183 million, showcasing the company's strong cash generation capability to support future R&D and market expansion.
- Optimistic Market Outlook: The company anticipates revenue growth of 6% to 7% in 2026, with adjusted EPS guidance of $4.15 to $4.25, indicating management's confidence in future business growth, particularly with ongoing investments in cardiopulmonary and epilepsy treatment areas.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LIVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LIVN
Wall Street analysts forecast LIVN stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 70.600
Low
64.00
Averages
72.50
High
85.00
Current: 70.600
Low
64.00
Averages
72.50
High
85.00
About LIVN
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LivaNova PLC Reports Strong Q4 2025 Earnings with Strategic Growth Plans
- Significant Performance Growth: LivaNova achieved revenue of $361 million in Q4 2025, reflecting a 9.5% year-over-year increase, demonstrating strong execution in cardiopulmonary and epilepsy segments, and marking the fifth consecutive year of double-digit EPS growth, which enhances market confidence.
- Market Expansion Strategy: The company is entering the obstructive sleep apnea market, with CEO emphasizing competitive advantages based on rigorous clinical evidence and differentiated technology, which is expected to drive future growth; Lucile Blaise has been appointed as Global Head of Commercialization to strengthen the leadership team.
- Financial Health Status: Adjusted gross margin remained at 68%, consistent with Q4 2024, while adjusted operating income rose to $64 million, a 14.3% increase from the prior year, indicating ongoing improvements in cost control and profitability.
- Optimistic Future Outlook: Management projects revenue growth of 6% to 7% for 2026, with cardiopulmonary expected to grow 7% to 8% and epilepsy growth forecasted at 5.5% to 6.5%, showcasing confidence in new product launches and market share expansion.
See More
LivaNova PLC Reports Strong Q4 2025 Earnings with Double-Digit Growth
- Significant Revenue Growth: LivaNova PLC reported Q4 2025 revenue of $361 million, a 9.5% increase, with cardiopulmonary revenue reaching $207 million, up 10% year-over-year, demonstrating strong performance in the medical device market and reinforcing its market position.
- Improved Profitability: The adjusted operating income stood at $64 million, maintaining an 18% margin consistent with the previous year, reflecting effective cost control and operational efficiency, which enhances confidence in future investments.
- Robust Cash Flow: By the end of 2025, LivaNova's cash balance reached $636 million, up from $429 million at the end of 2024, while adjusted free cash flow totaled $183 million, showcasing the company's strong cash generation capability to support future R&D and market expansion.
- Optimistic Market Outlook: The company anticipates revenue growth of 6% to 7% in 2026, with adjusted EPS guidance of $4.15 to $4.25, indicating management's confidence in future business growth, particularly with ongoing investments in cardiopulmonary and epilepsy treatment areas.
See More
LivaNova PLC Q4 Earnings Exceed Expectations
- Strong Earnings Performance: LivaNova PLC reported a Q4 non-GAAP EPS of $0.86, beating expectations by $0.05, which reflects the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $360.9 million, a 12.2% year-over-year increase, exceeding expectations by $65,900, indicating sustained demand for its products and driving overall performance.
- Optimistic Future Outlook: LivaNova expects full-year 2026 revenue growth between 6.0% and 7.0% on a constant-currency basis, reflecting the company's positive market outlook and strategic planning for future growth.
- Stable Cash Flow Expectations: Adjusted free cash flow is projected to be in the range of $160 million to $180 million, demonstrating the company's solid cash management and operational efficiency, which provides a foundation for future investments.
See More
LivaNova Options Trading Analysis
- Put Option Appeal: Selling the put option at a $62.50 strike price allows investors to collect a premium of $3.90, effectively lowering their cost basis to $58.60, which represents a 7% discount compared to the current stock price of $66.97, making it attractive for those interested in LIVN.
- Yield Potential Analysis: If the put option expires worthless, it would yield a 6.24% return on the cash commitment, or an annualized return of 13.81%, showcasing the YieldBoost potential of this strategy, appealing to investors seeking stable income.
- Call Option Returns: Selling the call option at a $70.00 strike price allows investors to collect a premium of $5.50, leading to a total return of 12.74% if the stock is called away at expiration, but significant upside could be missed if LIVN shares rise substantially.
- Risk Assessment: Current analytics indicate a 65% chance that the $62.50 put option will expire worthless, while the $70.00 call option has a 49% chance of doing so, prompting investors to weigh potential returns against risks to formulate optimal trading strategies.
See More
Tesla, Microsoft, and Meta Earnings Capture Attention
- Earnings Reports: Tesla, Microsoft, and Meta released their earnings after the stock market reached record highs, yet investor sentiment remains cautious regarding future performance expectations despite the positive results.
- Market Reaction: Following the earnings announcements, the overall market response was muted even though all three companies performed well, indicating investor concerns about sustained high valuations.
- Industry Impact: The earnings reports from these tech giants are likely to significantly influence investment sentiment across the tech sector, potentially leading other companies to adopt more conservative forecasts in their upcoming earnings.
- Investor Strategy: With the earnings releases, investors may reassess their portfolios, particularly in the context of high valuations in tech stocks, which could result in a shift of funds towards more value-oriented assets.
See More
Tesla, Microsoft, and Meta Report Strong Earnings
- Strong Earnings Reports: Tesla, Microsoft, and Meta released impressive earnings after the stock market reached record highs, showcasing robust revenue growth and profitability, which further solidifies investor confidence in tech stocks.
- Positive Market Reaction: Following the earnings announcements, stock prices for all three companies rose, reflecting market optimism regarding their future growth potential, particularly against the backdrop of a global economic recovery.
- Industry Leadership: Tesla maintains its lead in the electric vehicle market, Microsoft shows strong momentum in cloud computing, and Meta demonstrates significant innovation in social media and virtual reality, enhancing its competitive position in the market.
- Increased Investor Confidence: The release of these earnings not only boosts investor confidence in the tech sector but may also attract more capital into the field, potentially driving further market gains.
See More
LivaNova PLC Reports Strong Q4 2025 Earnings with Strategic Growth Plans
- Significant Performance Growth: LivaNova achieved revenue of $361 million in Q4 2025, reflecting a 9.5% year-over-year increase, demonstrating strong execution in cardiopulmonary and epilepsy segments, and marking the fifth consecutive year of double-digit EPS growth, which enhances market confidence.
- Market Expansion Strategy: The company is entering the obstructive sleep apnea market, with CEO emphasizing competitive advantages based on rigorous clinical evidence and differentiated technology, which is expected to drive future growth; Lucile Blaise has been appointed as Global Head of Commercialization to strengthen the leadership team.
- Financial Health Status: Adjusted gross margin remained at 68%, consistent with Q4 2024, while adjusted operating income rose to $64 million, a 14.3% increase from the prior year, indicating ongoing improvements in cost control and profitability.
- Optimistic Future Outlook: Management projects revenue growth of 6% to 7% for 2026, with cardiopulmonary expected to grow 7% to 8% and epilepsy growth forecasted at 5.5% to 6.5%, showcasing confidence in new product launches and market share expansion.
See More
LivaNova PLC Reports Strong Q4 2025 Earnings with Double-Digit Growth
- Significant Revenue Growth: LivaNova PLC reported Q4 2025 revenue of $361 million, a 9.5% increase, with cardiopulmonary revenue reaching $207 million, up 10% year-over-year, demonstrating strong performance in the medical device market and reinforcing its market position.
- Improved Profitability: The adjusted operating income stood at $64 million, maintaining an 18% margin consistent with the previous year, reflecting effective cost control and operational efficiency, which enhances confidence in future investments.
- Robust Cash Flow: By the end of 2025, LivaNova's cash balance reached $636 million, up from $429 million at the end of 2024, while adjusted free cash flow totaled $183 million, showcasing the company's strong cash generation capability to support future R&D and market expansion.
- Optimistic Market Outlook: The company anticipates revenue growth of 6% to 7% in 2026, with adjusted EPS guidance of $4.15 to $4.25, indicating management's confidence in future business growth, particularly with ongoing investments in cardiopulmonary and epilepsy treatment areas.
See More
LivaNova PLC Q4 Earnings Exceed Expectations
- Strong Earnings Performance: LivaNova PLC reported a Q4 non-GAAP EPS of $0.86, beating expectations by $0.05, which reflects the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $360.9 million, a 12.2% year-over-year increase, exceeding expectations by $65,900, indicating sustained demand for its products and driving overall performance.
- Optimistic Future Outlook: LivaNova expects full-year 2026 revenue growth between 6.0% and 7.0% on a constant-currency basis, reflecting the company's positive market outlook and strategic planning for future growth.
- Stable Cash Flow Expectations: Adjusted free cash flow is projected to be in the range of $160 million to $180 million, demonstrating the company's solid cash management and operational efficiency, which provides a foundation for future investments.
See More
LivaNova Options Trading Analysis
- Put Option Appeal: Selling the put option at a $62.50 strike price allows investors to collect a premium of $3.90, effectively lowering their cost basis to $58.60, which represents a 7% discount compared to the current stock price of $66.97, making it attractive for those interested in LIVN.
- Yield Potential Analysis: If the put option expires worthless, it would yield a 6.24% return on the cash commitment, or an annualized return of 13.81%, showcasing the YieldBoost potential of this strategy, appealing to investors seeking stable income.
- Call Option Returns: Selling the call option at a $70.00 strike price allows investors to collect a premium of $5.50, leading to a total return of 12.74% if the stock is called away at expiration, but significant upside could be missed if LIVN shares rise substantially.
- Risk Assessment: Current analytics indicate a 65% chance that the $62.50 put option will expire worthless, while the $70.00 call option has a 49% chance of doing so, prompting investors to weigh potential returns against risks to formulate optimal trading strategies.
See More
Tesla, Microsoft, and Meta Earnings Capture Attention
- Earnings Reports: Tesla, Microsoft, and Meta released their earnings after the stock market reached record highs, yet investor sentiment remains cautious regarding future performance expectations despite the positive results.
- Market Reaction: Following the earnings announcements, the overall market response was muted even though all three companies performed well, indicating investor concerns about sustained high valuations.
- Industry Impact: The earnings reports from these tech giants are likely to significantly influence investment sentiment across the tech sector, potentially leading other companies to adopt more conservative forecasts in their upcoming earnings.
- Investor Strategy: With the earnings releases, investors may reassess their portfolios, particularly in the context of high valuations in tech stocks, which could result in a shift of funds towards more value-oriented assets.
See More
Tesla, Microsoft, and Meta Report Strong Earnings
- Strong Earnings Reports: Tesla, Microsoft, and Meta released impressive earnings after the stock market reached record highs, showcasing robust revenue growth and profitability, which further solidifies investor confidence in tech stocks.
- Positive Market Reaction: Following the earnings announcements, stock prices for all three companies rose, reflecting market optimism regarding their future growth potential, particularly against the backdrop of a global economic recovery.
- Industry Leadership: Tesla maintains its lead in the electric vehicle market, Microsoft shows strong momentum in cloud computing, and Meta demonstrates significant innovation in social media and virtual reality, enhancing its competitive position in the market.
- Increased Investor Confidence: The release of these earnings not only boosts investor confidence in the tech sector but may also attract more capital into the field, potentially driving further market gains.
See More
